[go: up one dir, main page]

CL2018001512A1 - Anticuerpos anti-cd73 humanizados. - Google Patents

Anticuerpos anti-cd73 humanizados.

Info

Publication number
CL2018001512A1
CL2018001512A1 CL2018001512A CL2018001512A CL2018001512A1 CL 2018001512 A1 CL2018001512 A1 CL 2018001512A1 CL 2018001512 A CL2018001512 A CL 2018001512A CL 2018001512 A CL2018001512 A CL 2018001512A CL 2018001512 A1 CL2018001512 A1 CL 2018001512A1
Authority
CL
Chile
Prior art keywords
antibodies
document
humanized anti
humanized
humanized antibodies
Prior art date
Application number
CL2018001512A
Other languages
English (en)
Inventor
Emily Piccione Griffin
Richard A Miller
Gerhard Johann Frey
Hwai Wen Chang
Original Assignee
Corvus Pharmaceuticals Inc
Bioatla Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corvus Pharmaceuticals Inc, Bioatla Llc filed Critical Corvus Pharmaceuticals Inc
Publication of CL2018001512A1 publication Critical patent/CL2018001512A1/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/84—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving inorganic compounds or pH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Inorganic Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

SE PROPORCIONAN EN EL PRESENTE DOCUMENTO, ENTRE OTROS, ANTICUERPOS 1E9 HUMANIZADOS CAPACES DE UNIRSE AL CD73. LOS ANTICUERPOS HUMANIZADOS SON ÚTILES PARA EL TRATAMIENTO DEL CÁNCER. ADICIONALMENTE SE PROPORCIONAN EN EL PRESENTE DOCUMENTO ÁCIDOS NUCLÉICOS QUE CODIFICAN ANTICUERPOS 1E9 HUMANIZADOS Y MÉTODOS DE INHIBICIÓN DE LA PROLIFERACIÓN UTILIZANDO LOS  ANTICUERPOS HUMANIZADOS PROPORCIONADOS EN EL PRESENTE DOCUMENTO.
CL2018001512A 2015-12-09 2018-06-06 Anticuerpos anti-cd73 humanizados. CL2018001512A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562265357P 2015-12-09 2015-12-09
US201662289694P 2016-02-01 2016-02-01
US201662346327P 2016-06-06 2016-06-06

Publications (1)

Publication Number Publication Date
CL2018001512A1 true CL2018001512A1 (es) 2019-03-08

Family

ID=59013359

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2018001512A CL2018001512A1 (es) 2015-12-09 2018-06-06 Anticuerpos anti-cd73 humanizados.

Country Status (13)

Country Link
US (2) US10822426B2 (es)
EP (1) EP3387442A4 (es)
JP (2) JP7391510B2 (es)
KR (1) KR20180134837A (es)
CN (2) CN109154611B (es)
AU (1) AU2016366548C1 (es)
CA (1) CA3007646A1 (es)
CL (1) CL2018001512A1 (es)
EA (1) EA201891366A1 (es)
IL (1) IL259927B2 (es)
MX (1) MX2018006973A (es)
WO (1) WO2017100670A1 (es)
ZA (1) ZA201803874B (es)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017100670A1 (en) * 2015-12-09 2017-06-15 Corvus Pharmaceuticals, Inc. Humanized anti-cd73 antibodies
US10793636B2 (en) * 2016-07-11 2020-10-06 Corvus Pharmaceuticals, Inc. Anti-CD73 antibodies
WO2018137598A1 (en) 2017-01-24 2018-08-02 I-Mab Anti-cd73 antibodies and uses thereof
IL269150B2 (en) 2017-03-16 2025-04-01 Innate Pharma Cancer treatment preparations and methods
US20210107989A1 (en) * 2017-04-04 2021-04-15 Corvus Pharmaceuticals, Inc. Methods for treating cd73hi tumors
SG11202002192QA (en) 2017-10-06 2020-04-29 Innate Pharma Restoration of t cell activity via the cd39/cd73 axis
JP7474709B2 (ja) 2018-02-27 2024-04-25 インサイト・コーポレイション Ａ２ａ／ａ２ｂ阻害剤としてのイミダゾピリミジン及びトリアゾロピリミジン
CN110240654A (zh) * 2018-03-07 2019-09-17 复旦大学 结合cd73的抗体-药物偶联物
EP3762030A4 (en) * 2018-03-09 2022-01-05 Phanes Therapeutics, Inc. ANTI-CD73 ANTIBODIES AND USES THEREOF
TWI823906B (zh) * 2018-03-09 2023-12-01 美商艾吉納斯公司 抗-cd73 抗體及其使用方法
JP7611700B2 (ja) 2018-03-27 2025-01-10 ブリストル－マイヤーズ スクイブ カンパニー 紫外線シグナルを使用した力価のリアルタイムモニタリング
MA52940A (fr) 2018-05-18 2021-04-28 Incyte Corp Dérivés de pyrimidine fusionnés utilisés en tant qu'inhibiteurs de a2a/a2b
EP3569618A1 (en) * 2018-05-19 2019-11-20 Boehringer Ingelheim International GmbH Antagonizing cd73 antibody
TWI870353B (zh) 2018-06-18 2025-01-21 法商天賜製藥公司 用於治療癌症之組合物及方法
AU2019297361B2 (en) 2018-07-05 2024-06-27 Incyte Corporation Fused pyrazine derivatives as A2A / A2B inhibitors
CN112654365A (zh) 2018-07-12 2021-04-13 科尔沃斯制药股份有限公司 用于检测和治疗具有腺苷途径激活的癌症的方法
JP2021531751A (ja) 2018-07-12 2021-11-25 コーバス・ファーマシューティカルズ・インコーポレイテッド アデノシン経路活性化を有する癌を検出および治療するための方法
WO2020097127A2 (en) * 2018-11-05 2020-05-14 Corvus Pharmaceuticals, Inc. B-cell activating cd73 antibodies
BR112021007902A2 (pt) * 2018-11-12 2021-11-16 Jiangsu Hengrui Medicine Co Anticorpo anti-cd73, fragmento de ligação ao antigênio e aplicação dos mesmos
CN113727999A (zh) 2019-01-11 2021-11-30 奥默罗斯公司 用于治疗癌症的方法和组合物
CN111499747B (zh) * 2019-01-11 2022-03-18 康诺亚生物医药科技（成都）有限公司 一种抗cd73单克隆抗体及其应用
CN111434688A (zh) * 2019-01-11 2020-07-21 上海开拓者生物医药有限公司 Cd73抗体及其制备方法和应用
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
US20220135619A1 (en) 2019-02-24 2022-05-05 Bristol-Myers Squibb Company Methods of isolating a protein
EP3959239A1 (en) * 2019-04-23 2022-03-02 Innate Pharma Cd73 blocking antibodies
US20220220430A1 (en) 2019-05-23 2022-07-14 Bristol-Myers Squibb Company Methods of monitoring cell culture media
EA202193351A1 (ru) * 2019-06-06 2022-03-21 Джакобио Фармасьютикалс Ко., Лтд. Связывающая молекула, специфическая в отношении cd73, и применение связывающей молекулы
CN112300279A (zh) * 2019-07-26 2021-02-02 上海复宏汉霖生物技术股份有限公司 针对抗cd73抗体和变体的方法和组合物
CN113454121B (zh) * 2019-08-21 2022-03-08 和铂医药(上海)有限责任公司 抗cd73抗体及其应用
JP7662617B2 (ja) 2019-09-06 2025-04-15 レ ラボラトワール セルヴィエ 抗ｃｄ７３抗体
WO2021087463A1 (en) * 2019-11-01 2021-05-06 Corvus Pharmaceuticals, Inc. Immunomodulatory anti-cd73 antibodies and uses thereof
KR20220137013A (ko) 2020-01-03 2022-10-11 인사이트 코포레이션 Cd73 억제제 및 a2a/a2b 아데노신 수용체 억제제 병용 요법
EP4084825A1 (en) 2020-01-03 2022-11-09 Incyte Corporation Anti-cd73 antibodies and uses thereof
EP4132975A4 (en) * 2020-04-09 2024-10-23 Aprilbio Co., Ltd MONOCLONAL ANTIBODIES AND THEIR ANTIGEN-BINDING FRAGMENTS FOR SUPPRESSING THE CD73 IMMUNE CHECKPOINT AND USES THEREOF
CN113527489B (zh) * 2020-04-22 2024-04-26 中山康方生物医药有限公司 抗cd73的抗体及其用途
WO2021241729A1 (ja) * 2020-05-29 2021-12-02 ブライトパス・バイオ株式会社 抗ｃｄ７３抗体およびその用途
EP4169948A4 (en) 2020-06-22 2024-07-10 Innovent Biologics (Suzhou) Co., Ltd. ANTI-CD73 ANTIBODIES AND USE THEREOF
WO2022037531A1 (zh) * 2020-08-17 2022-02-24 中山康方生物医药有限公司 抗cd73的抗体及其用途
JP2023544410A (ja) 2020-10-05 2023-10-23 ブリストル－マイヤーズ スクイブ カンパニー タンパク質を濃縮するための方法
CA3196299A1 (en) * 2020-10-23 2022-04-28 Baiyong Li Anti-cd73 antibody and use thereof
US20240026024A1 (en) * 2020-12-11 2024-01-25 Shanghai Huaota Biopharmaceutical Co., Ltd. Cd73 antigen-binding protein and application thereof
TW202241441A (zh) 2020-12-29 2022-11-01 美商英塞特公司 包含ａ２ａ／ａ２ｂ抑制劑、ｐｄ－１／ｐｄ－ｌ１抑制劑及抗ｃｄ７３抗體之組合療法
WO2022179039A1 (zh) * 2021-02-24 2022-09-01 苏州近岸蛋白质科技股份有限公司 抗人cd73抗体及其应用
US12187806B2 (en) 2022-03-04 2025-01-07 Development Center For Biotechnology Anti-CD73 antibodies and use thereof
WO2023173011A1 (en) 2022-03-09 2023-09-14 Bristol-Myers Squibb Company Transient expression of therapeutic proteins
WO2023201267A1 (en) 2022-04-13 2023-10-19 Gilead Sciences, Inc. Combination therapy for treating trop-2 expressing cancers
CN115991772B (zh) * 2022-08-12 2023-09-01 南京蓬勃生物科技有限公司 抗cd73抗体或其抗原片段及其应用
EP4572772A1 (en) 2022-08-17 2025-06-25 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
EP4626552A1 (en) 2022-12-01 2025-10-08 MedImmune Limited Combination therapy for treatment of cancer comprising anti-pd-l1 and anti-cd73 antibodies
AU2024267583A1 (en) * 2023-05-07 2025-11-13 Bioatla, Inc. Protein therapeutics for treatment of senescent cells
WO2024249954A1 (en) 2023-05-31 2024-12-05 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
CN116813786B (zh) * 2023-08-03 2024-11-26 贝达药业股份有限公司 抗cd73抗体及其应用
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
WO2025076127A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025137640A1 (en) 2023-12-22 2025-06-26 Gilead Sciences, Inc. Azaspiro wrn inhibitors
US20250302763A1 (en) 2024-02-22 2025-10-02 Capstan Therapeutics, Inc. Immune engineering amplification
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles
WO2025233264A1 (en) 2024-05-07 2025-11-13 Innate Pharma Use of cd73 blocking agents in combination with anti-cd20 x cd3 t cell engagers

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
DK0585287T3 (da) 1990-07-10 2000-04-17 Cambridge Antibody Tech Fremgangsmåde til fremstilling af specifikke bindingsparelementer
EP0746609A4 (en) 1991-12-17 1997-12-17 Genpharm Int NON-HUMAN TRANSGENIC ANIMALS CAPABLE OF PRODUCING HETEROLOGOUS ANTIBODIES
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US6066718A (en) 1992-09-25 2000-05-23 Novartis Corporation Reshaped monoclonal antibodies against an immunoglobulin isotype
GB9815909D0 (en) * 1998-07-21 1998-09-16 Btg Int Ltd Antibody preparation
US6881557B2 (en) 2001-07-12 2005-04-19 Arrowsmith Technologies Llp Super humanized antibodies
US7456260B2 (en) * 2002-06-17 2008-11-25 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Humanized antibody
US20070134249A1 (en) * 2005-12-08 2007-06-14 Genitope Corporation Combination therapy and antibody panels
EP2535354B1 (en) * 2007-06-18 2017-01-11 Merck Sharp & Dohme B.V. Antibodies to human programmed death receptor pd-1
AR068723A1 (es) * 2007-10-05 2009-12-02 Glaxo Group Ltd Proteina que se une a antigenos que se une a il-23 humana y sus usos
JP2012504961A (ja) * 2008-10-06 2012-03-01 ミネルバ バイオテクノロジーズ コーポレーション Ｍｕｃ１＊抗体
WO2011091078A2 (en) * 2010-01-19 2011-07-28 Xencor, Inc. Antibody fc variants with enhanced complement activity
TW201134488A (en) * 2010-03-11 2011-10-16 Ucb Pharma Sa PD-1 antibodies
CN103068852B (zh) 2010-08-17 2016-04-20 弗·哈夫曼-拉罗切有限公司 抗人IgG1抗体
US9701742B2 (en) * 2011-07-01 2017-07-11 The Trustees Of The University Of Pennsylvania Anti-properdin antibodies and uses thereof
TW201922795A (zh) * 2012-09-10 2019-06-16 愛爾蘭商尼歐托普生物科學公司 抗ｍｃａｍ抗體及相關使用方法
WO2014130965A1 (en) 2013-02-22 2014-08-28 Amgen Inc. Gastrokine-1 (gkn1) binding proteins and methods of treatment
WO2014153424A1 (en) * 2013-03-19 2014-09-25 La Jolla Institute For Allergy And Immunology Reducing diabetes in patients receiving hmg-coa reductase inhibitors (statins)
ES2839087T3 (es) 2013-11-12 2021-07-05 Ogd2 Pharma Anticuerpo derivado de IGG1 humana con actividad pro-apoptótica
KR20160145813A (ko) * 2014-04-25 2016-12-20 다나-파버 캔서 인스티튜트 인크. 중동 호흡기 증후군 코로나바이러스 중화 항체 및 이의 사용 방법
EP3259288A1 (en) * 2015-02-20 2017-12-27 Innate Pharma Cd73 blockade
WO2017100670A1 (en) * 2015-12-09 2017-06-15 Corvus Pharmaceuticals, Inc. Humanized anti-cd73 antibodies

Also Published As

Publication number Publication date
EA201891366A1 (ru) 2018-12-28
EP3387442A4 (en) 2019-05-08
US20190077873A1 (en) 2019-03-14
JP7391510B2 (ja) 2023-12-05
CA3007646A1 (en) 2017-06-15
CN109154611A (zh) 2019-01-04
IL259927B1 (en) 2023-01-01
AU2016366548A1 (en) 2018-06-28
WO2017100670A1 (en) 2017-06-15
US10822426B2 (en) 2020-11-03
CN114805575A (zh) 2022-07-29
IL259927A (en) 2018-07-31
US11859007B2 (en) 2024-01-02
MX2018006973A (es) 2019-05-16
IL259927B2 (en) 2023-05-01
EP3387442A1 (en) 2018-10-17
CN109154611B (zh) 2022-04-08
JP2019503709A (ja) 2019-02-14
KR20180134837A (ko) 2018-12-19
JP2022104941A (ja) 2022-07-12
ZA201803874B (en) 2020-11-25
AU2016366548C1 (en) 2024-07-25
CN114805575B (zh) 2024-07-23
US20210253727A1 (en) 2021-08-19
AU2016366548B2 (en) 2023-12-14

Similar Documents

Publication Publication Date Title
CL2018001512A1 (es) Anticuerpos anti-cd73 humanizados.
MX2023007841A (es) Metodos, composiciones y componentes relacionados con crispr-cpf1 para la inmunoterapia contra el cancer.
CO2020016619A2 (es) Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso
CL2019002304A1 (es) Compuestos para el tratamiento del cáncer.
CO2017005784A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
MX2018005315A (es) Composiciones y metodos para el tratamiento del cancer.
CO2017007121A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
CL2018003316A1 (es) Compuestos para la inhibición de k-ras y para el tratamiento del cáncer. (divisional solicitud 201702786)
CO2017004516A2 (es) Anticuerpos anti-ox40 humanizados
BR112018003269A2 (pt) conjugados de fármaco-anticorpo anti-dll3 e métodos de utilização
MX381046B (es) Anticuerpos anti-csf1r e inhibidores de pd-1/pd-l1, y usos de los mismos para el tratamiento de cáncer remisión a las solicitudes relacionadas.
MX2017013178A (es) Terapia de combinacion para cancer.
EA201791485A1 (ru) Анти-cd47-антитела и их применения
MX389560B (es) Enfoque de inmunoterapias de combinación para el tratamiento del cancer.
TR201808169T3 (tr) Rekombinant probiyotik bakteriler .
BR112017004444A2 (pt) novos anticorpos anti-mfi2 e métodos de uso
CL2018002810A1 (es) Anticuerpos anti-factor bb del complemento y usos de estos referencia cruzada.
BR112018010279A2 (pt) novos anticorpos anti-emr2 e métodos de uso
BR112016017112A2 (pt) Composições de apilimod e métodos de uso das mesmas
MX395231B (es) Compuestos eficaces en el tratamiento de la hepatotoxicidad y enfermedades de hígado graso, y uso de los mismos.
EA201890747A1 (ru) Способы лечения воспалительных заболеваний
MX2018000715A (es) Metodos para tratar cancer usando apilimod.
AR100944A1 (es) ANTICUERPOS ANTAGONISTAS DE INTERFERÓN a Y w
MX374385B (es) Apilimod para uso en el tratamiento de melanoma.
CO2018008249A2 (es) Composiciones terapéuticas y métodos para el tratamiento de la hepatitis b